WO1999011763A9 - Method for purifying and concentrating aav-2 and antigen portions thereof - Google Patents
Method for purifying and concentrating aav-2 and antigen portions thereofInfo
- Publication number
- WO1999011763A9 WO1999011763A9 PCT/DE1998/002569 DE9802569W WO9911763A9 WO 1999011763 A9 WO1999011763 A9 WO 1999011763A9 DE 9802569 W DE9802569 W DE 9802569W WO 9911763 A9 WO9911763 A9 WO 9911763A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aav
- antibody
- chromatography material
- mgcl
- activated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
Definitions
- the present invention relates to a process for the purification of AAV-2 and antigenic parts thereof.
- viruses in particular recombinant viruses, which are used as vectors, have to be purified and concentrated.
- the object of the present invention is therefore to provide a method with which adeno-associated viruses of type 2 (AAV-2) can be purified and concentrated easily and efficiently from cell culture supernatants and cell extracts.
- AAV-2 adeno-associated viruses of type 2
- this object is achieved by a process for the purification and concentration of AAV-2 and antigenic parts thereof, which comprises the following steps: coupling an antibody directed against AAV-2 to an activated chromatography material,
- the method according to the invention is based on the principle of affinity chromatography graphic.
- an antibody directed against AAV-2 is bound to a chromatography material.
- the antibody is bound to the chromatography material according to known methods, for example as described in "Harlow and Lane, Antibodies (A Laboratory Manual), Cold Spring Harbor, 1 988".
- Suitable chromatography materials are the chromatography materials known to the person skilled in the art, in particular those hydrophilic materials which are known in connection with gel filtration. These are, for example, agarose gels (eg Sepharose R ), dextran gels (eg Sephadose R ), cellulose gel matrices and acrylamide geomatrices.
- the chromatography material is advantageously activated, which enables the binding and immobilization of proteins. This activation can take place by cyanogen bromide (CNBr) activation or NHS activation.
- CNBr cyanogen bromide
- AAV-2 or antigenic parts thereof can be a polycionic or monoclonal antibody.
- the antibody can be derived from any animal or human, with rabbits preferred for a polyclonal antibody and mice preferred for a monoclonal antibody.
- the antibody can be synthetic, parts or parts that are not necessary for the above recognition being missing in whole or in part or these parts being replaced by others which give the antibody further favorable properties. Parts outside the binding regions of the antibodies can also be modified, eliminated or replaced.
- DNA recombination technology is particularly suitable for the above measures. He is very familiar with this.
- A20 deposited with the DSMZ under DSM ACC21 94 on 1 October 3, 994.
- AAV-2 or antigenic parts thereof refers to AAV-2 capsid proteins, in particular VP1, VP2 and / or VP3 and their fragments that perform an antigenic function.
- AAV-2 includes both wild type and also recombinantly produced AAV-2.
- Methodological aspects of AAV-2 such as cell culture, virus growth, virus pre-purification, isolation of the proteins can be found in the relevant literature, e.g. B. in Handbook of Parvoviruses, Vol. I and II, CRC Press, Boca Raton, Florida, ED. P. Tjissen; Ruffing, M. et al. (1,992), J. Virol., 66, pp. 6922-6930.
- a solution containing AAV-2 is added to a chromatography column to which an antibody directed against AAV-2 is coupled, e.g. B. in the form of cell culture supernatants or cell extracts, there is binding to the immobilized antibody and AAV-2 can be detached therefrom, whereby a purification and concentration takes place.
- the elution conditions are almost neutral, approx. PH 6 to 8.
- the elution solution contains 0.5 to 4.5 M MgCl 2 , preferably 2-3 M MgCl 2 .
- the activated chromatography material can also contain spacers bound to it. These spacers are preferably aliphatic or cyclic hydrocarbon groups.
- the aliphatic hydrocarbon groups can be straight or branched ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl groups.
- the cyclic hydrocarbon groups include phenyl, benzyl and cyclohexyl groups.
- kits for carrying out the method according to the invention is also provided, which is also the subject of the present invention.
- a kit includes the following
- AAV-2 an antibody directed against AAV-2
- common tools such as buffers, chromatography matrix and controls.
- helper viruses adenoviruses
- Concentration from large volumes is also advantageous, with a yield of almost 100% being achievable.
- a scale-up of the method according to the invention is easily possible for large production quantities.
- Fig. 1 Principle of the method according to the invention
- Fig. 3 Graphic representation of the elution (light gray columns: wild type AAV-2; dark gray columns: rAAV-2)
- A20 antibody was affinity-purified from 500 ml of A20 hybridoma supernatant on an anti-mouse IgG column (alternatively, a "Quick Antibody Matrix from Dianova can be used). 8 mg of A20 antibody were applied
- HiTrap NSH-activated Sepharose (Pharmacia) coupled according to the manufacturer's instructions.
- the MgCl 2 can be removed by dialysis or pelleting of the virus particles and resuspension in a desired buffer (eg Tris or 1 0/1 TE).
- the A20 monoclonal antibody was removed from the hybridoma supernatant
- the column was washed continuously with PBS and the AAV-2 capsids were eluted with 2.5 M MgCl 2 in PBS supplemented with 50 mM Tris, pH 7.
- the A20 hitrap column was regenerated with PBS and stored under PBS / 0.01% sodium azide.
- the AAV-2 viruses were titrated by dot blot hybridization and immunofluorescence.
- Recombinant AAV-2 was also purified according to the above procedure for wild-type AAV-2.
- the expression of the LacZ gene was measured by in-situ X-Gal staining of the infected HeLa cells after serial dilutions (dark gray columns in FIG. 3).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98951251A EP1009809A2 (en) | 1997-09-02 | 1998-09-01 | Method for purifying and concentrating aav-2 and antigen portions thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19738292.4 | 1997-09-02 | ||
DE1997138292 DE19738292C1 (en) | 1997-09-02 | 1997-09-02 | Process for the purification and concentration of AAV-2 and antigenic parts thereof |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09508037 A-371-Of-International | 2000-06-23 | ||
US09/886,144 Continuation US20010031463A1 (en) | 1997-09-02 | 2001-06-20 | Method for purifying and concentrating AAV-2 and antigen portions thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1999011763A2 WO1999011763A2 (en) | 1999-03-11 |
WO1999011763A3 WO1999011763A3 (en) | 1999-05-14 |
WO1999011763A9 true WO1999011763A9 (en) | 1999-06-17 |
Family
ID=7840939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1998/002569 WO1999011763A2 (en) | 1997-09-02 | 1998-09-01 | Method for purifying and concentrating aav-2 and antigen portions thereof |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1009809A2 (en) |
DE (1) | DE19738292C1 (en) |
WO (1) | WO1999011763A2 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0725837B1 (en) * | 1993-10-28 | 2000-01-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Adeno-associated virus - its diagnostic use with early abortion |
AU722196B2 (en) * | 1995-08-30 | 2000-07-27 | Genzyme Corporation | Chromatographic purification of adenovirus and AAV |
-
1997
- 1997-09-02 DE DE1997138292 patent/DE19738292C1/en not_active Expired - Fee Related
-
1998
- 1998-09-01 WO PCT/DE1998/002569 patent/WO1999011763A2/en not_active Application Discontinuation
- 1998-09-01 EP EP98951251A patent/EP1009809A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO1999011763A3 (en) | 1999-05-14 |
EP1009809A2 (en) | 2000-06-21 |
WO1999011763A2 (en) | 1999-03-11 |
DE19738292C1 (en) | 1999-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1198580B1 (en) | Scleroprotein of an adeno-associated virus with modified chromatographic properties, the production thereof and use of the same | |
DE69737364T2 (en) | METHODS FOR VIRUS CLEANING | |
DE69636217T2 (en) | PROCESS FOR PURIFICATION OF RECOMBINANT, VIRAL VECTORS CONTAINING A THERAPEUTIC GENE | |
DE69927013T2 (en) | EFFICIENT CLEANING OF ADENOVIRUS | |
EP1198581B1 (en) | Method for reducing the antigenicity of adeno-associated virus structural protein | |
DE19543553B4 (en) | VP antigens of the JC virus | |
DE19827457C1 (en) | Structural protein of AAV, its production and use | |
DE10066104A1 (en) | Host cells for packaging recombinant adeno-associated virus (rAAV), process for their preparation and their use | |
DE19709186C2 (en) | Filtration process for the separation of viruses | |
DE69019359T2 (en) | HUMAN PARVOVIRUS B19 PROTEINS AND VIRUS-LIKE PARTICLES, THEIR PRODUCTION AND THEIR USE IN DIAGNOSTIC TESTS AND VACCINES. | |
DE102005047301B4 (en) | Method for detection of virus depletion for the validation of filters and filtration processes | |
DE19738292C1 (en) | Process for the purification and concentration of AAV-2 and antigenic parts thereof | |
WO1991012269A1 (en) | Immunologically active peptides or polypeptides from the parvovirus b19 | |
EP1362125B8 (en) | METHOD FOR IDENTIFYING of BIOLOGICALLY ACTIVE STRUCTURES OF MICROBIAL PATHOGENS | |
EP0934423B1 (en) | Aav-dna helper virus sequences | |
US20010031463A1 (en) | Method for purifying and concentrating AAV-2 and antigen portions thereof | |
Brady et al. | Stable association of viral protein VP1 with simian virus 40 DNA | |
WO1982003408A1 (en) | Method for the preparation of a dna-hybride,containing the complementary genome of the hepatitis a virus,the dna-hybride itself,the plasmic vector contain it,the specific proteins of the virus coded by the dna-hybride and vaccins containing them | |
DE3883596T2 (en) | Purification of recombined hepatitis B surface antigen. | |
DE3939200A1 (en) | ENTEROVIRAL POLYPEPTIDES AND GROUP-SPECIFIC DETECTION OF ENTEROVIRUS INFECTIONS | |
DE19744655C2 (en) | Antibodies against baculoviruses | |
EP0419446B1 (en) | A complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen | |
EP0228568B1 (en) | Carrier bioactivated by antibodies covalently bound to its surface | |
EP0449170A1 (en) | Cellular binding protein with affinity for human type 18 papilloma virus regulatory region |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGE 3/3, DRAWINGS, REPLACED BY A NEW PAGE 3/3; AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZEDBY THE INTERNATIONAL SEARCHING AUTHORITY |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998951251 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998951251 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09508037 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998951251 Country of ref document: EP |